Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun organic chemistry The N-
acetyl derivative ofgalactosamine that is a repeat unit inglycosaminoglycans
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word acetylgalactosamine.
Examples
-
In 1947 he discovered, in collaboration with Stone, the receptor-destroying enzyme present in Vibrio cholerae, a discovery which led to the synthesis of neuraminic acid and to the demonstration, by Gottschalk and Cornforth, that purified influenza virus will quantitatively split the acetylgalactosamine neuraminic acid compound.
-
(N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy.
Medindia Health News 2010
-
N-acetylgalactosamine (GalNAc), as a ligand for the targeted delivery of RNAi therapeutics.
-
Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6-sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS).
-
N-acetylgalactosamine (GalNAc), as a ligand for the targeted delivery of RNAi therapeutics.
-
(N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy.
Medindia Health News 2010
-
GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy.
-
Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU.
-
GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy.
-
Apart from BMN 673, interesting candidates at BioMarin include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in development for the treatment of phenylketonuria (PKU) and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in development for the treatment of mucopolysaccharidosis IVA - a rare genetic enzyme deficiency disorder.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.